Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Cancer Research|June 27, 2015
A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical EfficacyAlexander V Yurkovetskiy, Mao Yin, Natalya Bodyak, et al.
Environmental Science & Technology|January 27, 2017
Origin of Magnetism in Hydrothermally Aged 2-Line Ferrihydrite SuspensionsLiang Cao, Zhao-Xia Jiang, Yong-Hua Du, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2022
Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugatesJoshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, et al.
Journal of Translational Medicine|May 9, 2026
Integrative single-cell and spatial multi-Omics analyses identify NETs-driven colon cancer subtypes with distinct metabolic features and prognostic implicationsXiao-Long Tang, Yi He, Wen-Yu Luan, et al.
Molecular Cancer Therapeutics|February 14, 2024
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug ConjugatesJoshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, et al.
International Journal of Surgery (London, England)|February 12, 2026
Global, regional, and national burdens of colorectal cancer and inflammatory bowel disease, 1990-2021 and projections to 2050: a cross-sectional studyZheng Zhang, Xiao-Long Tang, Rui Ma, et al.
The Lancet. Gastroenterology & Hepatology|November 12, 2023
Effect of an artificial intelligence-assisted system on endoscopic diagnosis of superficial oesophageal squamous cell carcinoma and precancerous lesions: a multicentre, tandem, double-blind, randomised controlled trialXiang-Lei Yuan, Wei Liu, Yi-Xiu Lin, et al.
Molecular Cancer Therapeutics|March 16, 2021
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander EffectAleksandr V Yurkovetskiy, Natalya D Bodyak, Mao Yin, et al.
Molecular Cancer Therapeutics|March 16, 2021
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2bNatalya D Bodyak, Rebecca Mosher, Aleksandr V Yurkovetskiy, et al.
Molecular Cancer Therapeutics|June 9, 2023
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of CancerDorin Toader, Shawn P Fessler, Scott D Collins, et al.
Pageof 6